title: [ABO-incompatible liver transplantation for liver failure].
abstract: OBJECTIVE
  To evaluate the efficacy of ABO-incompatible orthotopic liver transplantation (OLT) in treatment of liver failure.
  
  
  METHODS
  The clinical data of 66 cases of OLT, including 21 cases of ABO-incompatible OLT, for liver failure were retrospectively analyzed.
  
  
  RESULTS
  The 3-month, and 1-, 2-, and 3-year survival rates of the ABO-identical group were 84.2%, 77.4%, 67.6%, and 60.1%, respectively, while those of the ABO-incompatible group were 75.6%, 64.0%, 58.2%, and 58.2%, respectively. The mean survival time of the ABO-identical group was (806.0+/-70.0) d, not significantly different from that of the ABO-incompatible group (720.3+/-118.5 d, P=0.417). The acute rejection rate of the ABO-identical group was 8.9%, not significantly different from that of ABO-incompatible group (9.0%, P=0.253). The biliary tract complication rate and infection rate of the ABO-incompatible group were 76.2% and 28.6% respectively, both significantly higher than those of the ABO-identical group (48.9% and 8.9% respectively, P=0.037 and P=0.038). The major causes of death in the ABO-incompatible group were serious infection (5/21) and renal failure (4/21).
  
  
  CONCLUSIONS
  ABO-incompatible OLT is an acceptable option to cure liver failure in emergency. Intensive perioperative supervision is essential to improve the effect of ABO-incompatible OLT.
authors.affiliation: Liver Transplant Center, Third Affiliated Hospital of Sun Yat-sen University, Transplantation Research Institute of Sun Yat-sen University, Guangzhou 510630, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Yang
authors.forename: Chi
authors.initials: C
authors.lastname: Xu
authors.forename: Ying-hua
authors.initials: YH
authors.lastname: Chen
authors.forename: Min-qiang
authors.initials: MQ
authors.lastname: Lu
authors.forename: Chang-jie
authors.initials: CJ
authors.lastname: Cai
authors.forename: Hua
authors.initials: H
authors.lastname: Li
authors.forename: Gen-shu
authors.initials: GS
authors.lastname: Wang
authors.forename: Shu-hong
authors.initials: SH
authors.lastname: Yi
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.forename: Hui-min
authors.initials: HM
authors.lastname: Yi
authors.forename: Jun-feng
authors.initials: JF
authors.lastname: Zhang
authors.forename: Nan
authors.initials: N
authors.lastname: Jiang
authors.forename: Hui
authors.initials: H
authors.lastname: Zhao
authors.forename: Xi
authors.initials: X
authors.lastname: Li
authors.forename: Min-ru
authors.initials: MR
authors.lastname: Li
authors.forename: Gui-hua
authors.initials: GH
authors.lastname: Chen
mesh_terms: D000017:ABO Blood-Group System; D000328:Adult; D000368:Aged; D001787:Blood Group Incompatibility / Q000150:complications*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000209:etiology / Q000401:mortality; D006085:Graft Survival; D006801:Humans; D017093:Liver Failure / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D000017:ABO Blood-Group System